317 related articles for article (PubMed ID: 17269700)
1. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli.
Kang H; Sun AY; Shen YL; Wei DZ
Biotechnol Prog; 2007; 23(1):286-92. PubMed ID: 17269700
[TBL] [Abstract][Full Text] [Related]
2. Soybean disease resistance protein RHG1-LRR domain expressed, purified and refolded from Escherichia coli inclusion bodies: preparation for a functional analysis.
Afzal AJ; Lightfoot DA
Protein Expr Purif; 2007 Jun; 53(2):346-55. PubMed ID: 17287130
[TBL] [Abstract][Full Text] [Related]
3. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Lin Z; Lei H; Cao P
Protein Expr Purif; 2007 Feb; 51(2):276-82. PubMed ID: 17079165
[TBL] [Abstract][Full Text] [Related]
4. [High-cell density cultivation of recombinant Escherichia coli for production of TRAIL by using a 2-stage feeding strategy].
Zhang Y; Shen YL; Xia XX; Sun AY; Wei DZ; Zhou JS; Zhang GJ; Wang LH; Jiao BH
Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):408-13. PubMed ID: 15971615
[TBL] [Abstract][Full Text] [Related]
5. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
6. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase.
Gasparian ME; Ostapchenko VG; Yagolovich AV; Tsygannik IN; Chernyak BV; Dolgikh DA; Kirpichnikov MP
Biotechnol Lett; 2007 Oct; 29(10):1567-73. PubMed ID: 17609857
[TBL] [Abstract][Full Text] [Related]
7. Optimization of culture on the overproduction of TRAIL in high-cell-density culture by recombinant Escherichia coli.
Luo Q; Shen YL; Wei DZ; Cao W
Appl Microbiol Biotechnol; 2006 Jun; 71(2):184-91. PubMed ID: 16215715
[TBL] [Abstract][Full Text] [Related]
8. Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy.
Sun AY; Shen YL; Yin JC; Zhang H; Tang YN; Wei DZ
Biotechnol Lett; 2006 Aug; 28(15):1215-9. PubMed ID: 16799759
[TBL] [Abstract][Full Text] [Related]
9. Protein expression and refolding--a practical guide to getting the most out of inclusion bodies.
Cabrita LD; Bottomley SP
Biotechnol Annu Rev; 2004; 10():31-50. PubMed ID: 15504702
[TBL] [Abstract][Full Text] [Related]
10. Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in Escherichia coli.
Hu ZM; Ma L; Zhou MQ; Gao JM; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1083-6. PubMed ID: 16939889
[TBL] [Abstract][Full Text] [Related]
11. On-column refolding and purification of recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) expressed as inclusion body in Escherichia coli.
Tan H; Dan G; Gong H; Cao L
Biotechnol Lett; 2005 Aug; 27(16):1177-82. PubMed ID: 16158260
[TBL] [Abstract][Full Text] [Related]
12. Techno-economic evaluation of an inclusion body solubilization and recombinant protein refolding process.
Freydell EJ; van der Wielen LA; Eppink MH; Ottens M
Biotechnol Prog; 2011; 27(5):1315-28. PubMed ID: 21674819
[TBL] [Abstract][Full Text] [Related]
13. Refolding and purification of Apo2l/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli.
Shen YL; Xia XX; Zhang Y; Liu JW; Wei DZ; Yang SL
Biotechnol Lett; 2003 Dec; 25(24):2097-101. PubMed ID: 14969416
[TBL] [Abstract][Full Text] [Related]
14. A novel protein refolding method using a zeolite.
Chiku H; Kawai A; Ishibashi T; Takehara M; Yanai T; Mizukami F; Sakaguchi K
Anal Biochem; 2006 Jan; 348(2):307-14. PubMed ID: 16316618
[TBL] [Abstract][Full Text] [Related]
15. [Cloning, expression and purification of human TNF-related apoptosis-inducing ligand in Escherichia coli].
Yao GH; Luan JF; Ye D; Lei QH; Zhu PY; Jin J; Hou YY
Wei Sheng Yan Jiu; 2006 Nov; 35(6):697-700. PubMed ID: 17290744
[TBL] [Abstract][Full Text] [Related]
16. High throughput purification of recombinant human growth hormone using radial flow chromatography.
Singh SM; Sharma A; Panda AK
Protein Expr Purif; 2009 Nov; 68(1):54-9. PubMed ID: 19500673
[TBL] [Abstract][Full Text] [Related]
17. Refolding and purification of unprocessed porcine myostatin expressed in Escherichia coli.
Jin HJ; Dunn MA; Borthakur D; Kim YS
Protein Expr Purif; 2004 May; 35(1):1-10. PubMed ID: 15039059
[TBL] [Abstract][Full Text] [Related]
18. Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration.
Vallejo LF; Rinas U
Biotechnol Bioeng; 2004 Mar; 85(6):601-9. PubMed ID: 14966801
[TBL] [Abstract][Full Text] [Related]
19. Direct refolding of inclusion bodies using reversed micelles.
Sakono M; Kawashima YM; Ichinose H; Maruyama T; Kamiya N; Goto M
Biotechnol Prog; 2004; 20(6):1783-7. PubMed ID: 15575712
[TBL] [Abstract][Full Text] [Related]
20. Solid-state NMR spectroscopy reveals that E. coli inclusion bodies of HET-s(218-289) are amyloids.
Wasmer C; Benkemoun L; Sabaté R; Steinmetz MO; Coulary-Salin B; Wang L; Riek R; Saupe SJ; Meier BH
Angew Chem Int Ed Engl; 2009; 48(26):4858-60. PubMed ID: 19472238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
